biostudies-literatureOu FSDaniel J. Sargent, Career Development Award in Cancer Research (FSO)NCI NIH HHSARCAD Foundation4117https://www.ebi.ac.uk/biostudies/studies/S-EPMC10452983biostudies-literatureUnknown15(16)Metastatic colorectal cancer (mCRC) is a heterogeneous disease that can evoke discordant responses to therapy among different lesions in individual patients. The Response Evaluation Criteria in Solid Tumors (RECIST) criteria do not take into consideration response heterogeneity. We explored and developed lesion-based measurement response criteria to evaluate their prognostic effect on overall survival (OS).<h4>Patients and methods</h4>Patients enrolled in 17 first-line clinical trials, who had mCRC with ≥ 2 lesions at baseline, and a restaging scan by 12 weeks were included. For each patient, lesions were categorized as a progressing lesion (PL: > 20% increase in the longest diameter (LD)), responding lesion (RL: > 30% decrease in LD), or stable lesion (SL: neither PL nor RL) based on the CancersEvaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database.PMC10452983P30 CA008748Diaz-Rubio EShi QLou YKoopman MChibaudel BVan Cutsem EHurwitz HDixon JGVenook APSchmoll HJGrothey AHubbard JMBekaii-Saab TZalcberg JGoldberg RMOu FSAhn DHDouillard JYKabbinavar FFKasi PMBokemeyer CSaltz LBFuchs CSCremolini Cde Gramont APunt CJATebbutt NCAdams RAHecht JRHoff PYoshino TfalseEvaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database.Metastatic colorectal cancer (mCRC) is a heterogeneous disease that can evoke discordant responses to therapy among different lesions in individual patients. The Response Evaluation Criteria in Solid Tumors (RECIST) criteria do not take into consideration response heterogeneity. We explored and developed lesion-based measurement response criteria to evaluate their prognostic effect on overall survival (OS).<h4>Patients and methods</h4>Patients enrolled in 17 first-line clinical trials, who had mCRC with ≥ 2 lesions at baseline, and a restaging scan by 12 weeks were included. For each patient, lesions were categorized as a progressing lesion (PL: > 20% increase in the longest diameter (LD)), responding lesion (RL: > 30% decrease in LD), or stable lesion (SL: neither PL nor RL) based on the 2023-01-01T00:00:00Z2023 Aug2026-05-07T03:14:52.994Z2025-04-04T07:13:21.98ZS-EPMC104529833762714510.3390/cancers15164117